BioSpace News Archive

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for Pipeline™ Flex Embolization Device with Shield Technology™

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the acceptance by the U.S. Food and Drug Administration (FDA) of Pharvaris’ Investigational New Drug (IND) application for the prophylactic study of PHVS416,

Feedtrail, a leading experience management company, in partnership with HOLLIBLU, an exclusive community and technology for nurses, announces the results of a new nationwide survey of nurses, giving a glimpse into how communication and engagement impacted vaccine perceptions

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders inside and outside of the brain, today announced that Milton Werner, Ph.D., President and Chief Executive Officer,

111, Inc., a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, announced that it will report its unaudited financial results for the first quarter ended March 31, 2021, before the U.S. market opens on Wednesday, May 19, 2021.

Recursion Pharmaceuticals, Inc. (“Recursion” or “we”) announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase 3,636,363 additional shares of its Class A common stock, at a price to the public of $18.00 per share.

Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, announced the close of a $40 million Series A financing led by impact investor, The Craftory, alongside TechBio investor ARTIS Ventures and life science investor GISEV, with participation from existing investors, Founders Fund and 8VC.

Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today announced ACUVUE® Abiliti™ – a new brand for future products and services to help parents and eye care providers address the growing prevalence and progression of myopia in children.

The collaboration will provide access to life-changing vitamins and minerals to more than 100,000 nutritionally vulnerable women and children around the world.

North America’s leading Thyroid Surgery Center has established the Suh Scarless Thyroid Surgery Center in Tampa Florida, to provide the best robotic thyroid surgery for scarless removal of thyroid cancers, thyroid goiters, and thyroid nodules.